**Background of BIRC5 Antibody**
BIRC5 (Baculoviral IAP Repeat-Containing 5), also known as survivin, is a member of the inhibitor of apoptosis protein (IAP) family. It plays a dual role in regulating cell division and inhibiting programmed cell death (apoptosis). Structurally, BIRC5 contains a conserved baculovirus IAP repeat (BIR) domain critical for its anti-apoptotic function and interacts with microtubules during mitosis.
BIRC5 is highly expressed in embryonic tissues but is typically absent in most differentiated adult cells. However, its overexpression is strongly associated with numerous cancers, including breast, lung, colorectal, and pancreatic malignancies. This upregulation correlates with tumor progression, resistance to therapy, and poor prognosis, making BIRC5 a promising diagnostic and therapeutic target.
Antibodies targeting BIRC5 are widely used in research to detect its expression and localization in cells and tissues. These antibodies enable techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in the study of BIRC5's role in cancer biology, drug resistance mechanisms, and cell cycle regulation. Additionally, BIRC5-specific antibodies are explored in therapeutic strategies, such as monoclonal antibody therapies or CAR-T cell engineering, to selectively target cancer cells.
Overall, BIRC5 antibodies serve as vital tools for understanding cancer pathogenesis and developing precision oncology approaches.